CN108402371A - 一种适合中老年便秘人群服用的益生元组合物 - Google Patents
一种适合中老年便秘人群服用的益生元组合物 Download PDFInfo
- Publication number
- CN108402371A CN108402371A CN201810051008.9A CN201810051008A CN108402371A CN 108402371 A CN108402371 A CN 108402371A CN 201810051008 A CN201810051008 A CN 201810051008A CN 108402371 A CN108402371 A CN 108402371A
- Authority
- CN
- China
- Prior art keywords
- constipation
- probiotics
- inulin
- vitamin
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 39
- 229920001202 Inulin Polymers 0.000 claims abstract description 31
- 229940029339 inulin Drugs 0.000 claims abstract description 31
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 31
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 19
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 19
- 239000011718 vitamin C Substances 0.000 claims abstract description 19
- 235000013361 beverage Nutrition 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 6
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 33
- 239000006041 probiotic Substances 0.000 abstract description 30
- 235000018291 probiotics Nutrition 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 28
- 241000186000 Bifidobacterium Species 0.000 abstract description 18
- 230000012010 growth Effects 0.000 abstract description 17
- 238000010521 absorption reaction Methods 0.000 abstract description 13
- 239000005715 Fructose Substances 0.000 abstract description 11
- 229930091371 Fructose Natural products 0.000 abstract description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 11
- 210000000936 intestine Anatomy 0.000 abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 9
- 230000002650 habitual effect Effects 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 8
- -1 oligofructose Chemical compound 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 5
- 244000005709 gut microbiome Species 0.000 abstract description 5
- 239000013589 supplement Substances 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000001079 digestive effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 230000013872 defecation Effects 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 8
- 239000000976 ink Substances 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229960004192 diphenoxylate Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001141 propulsive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 108010011619 6-Phytase Proteins 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229940085127 phytase Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 241001532014 Xanthorrhoea Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种适合中老年便秘人群服用的益生元组合物,中老年人便秘单独补充某种益生菌很难达到润肠通便的作用的,本发明采用菊粉、低聚果糖、维生素C与果糖四种成分,按照6~15:3~8:0.03~0.10:1~5份组成的治疗中老年人便秘的组合物,可调节肠道微生物菌群,促进肠道双歧杆菌等益生菌的数量,组合物中的维生素C也有促进肠道原有的益生菌成长,还可以调节益生菌的生长环境,抗病毒,促进免疫功能,果糖能够提供胃肠道的吸收和消化及肠蠕动的关键能量,更好促进胃肠道的吸收和消化功能,增强肠的蠕动功能,达到润肠通便,解除习惯性便秘,顽固性便秘等症状,本品没有毒性,特别适合中老年人保健及防治习惯性便秘。
Description
技术领域
本发明属于食品技术领域,具体涉及一组适合中老年便秘人群服用的益生元固体饮料的配方及生产工艺。
背景技术
便秘是临床最常见的复杂的消化道疾病,也是其他疾病的并发症。随着社会经济的发展,随着人们饮食结构和生活***衡紊乱,引起痔疮、下肢静脉曲张等疾病。长期的便秘可使肠道细菌发酵而产生的致癌物质刺激肠黏膜上皮细胞,导致异形增生,易诱发癌变。一项***评价资料显示,世界各地报道的成人便秘发生率在2.5~79%之间。便秘的发生率基本上随着年龄的增长呈上升的趋势,我国不同地区不同人群 60岁以上人群的便秘发生率在4.97~23.01%;女性便秘人数要多于男性。便秘多由饮食、排便***衡、免疫功能、胃肠道发育及其它多种重要的生理活动。同时,研究发现糖尿病、肥胖症、高血压等代谢类疾病的患者的肠道菌群结构与健康人群不同,虽然目前还不清楚究竟是肠道微生物菌群的变化引起了代谢类疾病的发生,还是代谢类疾病的发生导致了肠道微生物菌群的变化,但是有一点可以肯定:通过改变肠道微生物菌群的构成,对人体的健康产生影响,同时也可能对某些疾病的治疗提供帮助。人体生物学是由人体基因组和人体微生物组两部分组成的,其中人体基因组的改变是极为困难的,但是人体肠道内微生物构成的改变相对比较容易。饮食、抗生素类药物以及环境等因素均可以影响个体肠道菌群的组成,其中以饮食因素影响最大。研究发现直接服用富含益生菌菌株的胶囊及其发酵乳制品,可以将大量活性益生菌菌株送达人体肠道,从而直接并有效地对人体的肠道微生物组成产生影响。益生菌,是指定植于人体肠道内,能产生确切健康功效的活的有益微生物的总称。益生菌主要包括乳杆菌(Lactobacillus)和双歧杆菌(Bifidobacterim),其益生作用主要是通过直接或者间接的调整宿主肠道微生物的组成,激活宿主内源性微生物群或者免疫***的活性来实现的。口服益生菌能够治愈或缓解多种胃肠道或与胃肠道相关的疾病。目前研究证实口服益生菌有助于缓解便秘及肠道感染,预防或者治愈胃肠炎、抗生素相关性腹泻、同时可抑制有害微生物在宿主肠道中定植,对肠易激综合征、炎症性肠炎及结肠癌等肠道相关性疾病具有良好的预防和治疗作用。
虽然人们对益生菌和肠道菌群关系已经有了初步的了解,但肠道菌群影响因素复杂,人未出生前一直是在一个无菌的环境中,肠道菌群显然是后天获得的。肠道菌群构成复杂,而影响肠道菌群的因素更是种类繁多。其中,饮食习惯和环境差异对肠道菌群的组成关系密切,抗生素的干扰也可导致人肠道中定居细菌的改变,此外,遗传因素、健康状况甚至吸烟与否都会对肠道菌群带来影响,因此,补充某种活的“益生菌”,对改善人体肠道功能,达到润肠通便的目标往往收效不大,这也成为了研究人员争论的焦点。本项目研究人员认为,单独补充某种益生菌很难达到润肠通便的作用的,我们应该通过采用菊粉、低聚果糖等一些能够激活人体自身存在的有益的肠道益生菌的功能的物质来设法激活人体自身存在的益生菌,同时,为了促进这些肠道益生菌健康生长、繁殖,我们还要添加一些果糖、维生素C等一些能量物质及抑制其他肠道非益生菌生长的物质,调节好肠道适合益生菌生长的环境条件,这样,就可以使肠道已有的益生菌能够健康成长,从而解决消化道糖、蛋白质、脂肪和矿物质的吸收和消化,改善肠道菌群的作用,进而达到润肠通便,改善慢性便秘的作用,保证身体的健康。
菊粉是植物中储备性多糖,主要来源于植物,已发现有36000多种,包括双子叶植物中的菊科、桔梗科、龙胆科等11个科及单子叶植物中的百合科、禾木科。菊粉可调节肠道微生物菌群,改善肠道健康,防止便秘:菊粉是一种天然的水溶性膳食纤维,几乎不能被胃酸水解和消化,只有在结肠被有益微生物利用,从而改善肠道环境。有研究证明菊粉可促进结肠内双歧杆菌以40倍递增的速度增殖。成年人每天摄入10g菊粉低聚糖,一周后每克粪便中的双歧杆菌数增加20%。每天摄入10g菊粉低聚糖,3周之内即可减少44.6%有毒发酵产物和40.9%有害细菌酶的产生。也有报道菊粉促进双歧杆菌的增殖程度取决于人体大肠中初始双歧杆菌的数量,当初始双歧杆菌数量减少时,使用菊粉后增殖效果明显,当初始双歧杆菌的数量多时,使用菊粉后效果并不明显。其次,摄入菊粉后能增强胃肠道蠕动,提高肠胃功能,增加消化和食欲,提高机体免疫力。菊粉还可抑制有毒发酵产物的生成,保护肝脏,预防结肠癌,食物经消化吸收后到达结肠,在肠道腐生菌(大肠杆菌、拟杆菌等)的作用下,可产生许多有毒的代谢产物(如氨、亚硝胺、苯酚与甲苯酚、次级胆汁酸等),而菊粉在结肠被发酵产生的短链脂肪酸能够降低结肠PH,抑制腐生菌的生长,减少有毒产物的生成,减少其对肠壁的刺激,菊粉一系列代谢活动能抑制有毒物质产生,增加排便次数和重量,增加粪便酸度,加速致癌物的***,产生有抗癌作用的短链脂肪酸,有利于预防结肠癌。菊粉还可减少食物在胃肠的停留时间,以及增加粪便量,有效地治疗便秘,菊粉可以通过提高食物内容物的黏度,降低食物从胃进入小肠的速度,从而降低饥饿感,减少食物的摄食量而发挥减肥作用。菊粉可提高食物中Ca2+、Mg2+、Zn2+、Cu2+、Fe2+等矿物质的吸收,有报道青少年食用8g/d长和短链菊粉型果聚糖分别8周和1年,结果发现,都显著提高Ca2+吸收,而且身体的骨骼矿物质含量和密度也显著增加。菊粉促进矿物质元素吸收的主要机制是:1)菊粉在结肠发酵生成的短链脂肪使其黏膜上的隐窝变浅,隐窝细胞增多从而增大了吸收面积,盲肠静脉更发达。2)发酵所产生的酸降低结肠PH,使得许多矿物质的溶解度、生物有效性得以提高,特别是短链脂肪酸可以刺激结肠粘膜细胞的生长,提高肠黏膜的吸收能力;3)菊粉能促进一些微生物分泌植酸酶,植酸酶能使与植酸螯合的金属离子释放出来,促进其吸收。4)发酵生成的某些有机酸可与金属离子螯合,促进金属离子吸收。菊粉还有降低血糖和调节血脂作用,临床应用菊粉能降低血糖的作用,减轻糖尿病的症状;临床应用菊粉帮助消化和增强肠的蠕动功能,用于治疗习惯性便秘,顽固性便秘;临床还应用菊粉调整肠胃的运动,促进对维他命以及微量元素的吸收的作用,用于身体保健,增强运动,促进体内能量的消耗,从而达到减肥的目的。
低聚果糖是指果糖基经β-2,1糖苷键连接而成的聚合度为2~9的功能性低聚糖,属于食品配料。低聚果糖可改善肠道菌群、减轻便秘症状、改善脂质代谢、抑制肠道腐败、促进钙镁等矿质元素的吸收、增强免疫力等。研究表明每日摄食3.3g的低聚果糖可调节人体肠道菌群,激活益生菌增殖并抑制有害菌的生长,说明低聚果糖可选择性的增殖双歧杆菌,从而调节肠道微生态平衡,维持肠道健康。有人将120例体检指标合格的成年志愿者随机分为空白对照组和试食组,试食组每天服用 6mL 含量大于等于55%的低聚果糖,对照组则以果葡糖浆作为安慰剂,连续进行30天后,通过试验组试验前后人体肠道菌群自身比较差异性以及试验后试验组与对照组组间比较的差异性分析,观察到每日摄食3.3g的低聚果糖可调节人体肠道菌群,激活益生菌增殖并抑制有害菌的生长。还有人观察了不同剂量低聚果糖对小鼠肠道菌群的影响,观察到连续灌胃给予低聚果糖7天,高剂量组小鼠肠道双歧杆菌数量增加,中、低剂量组双歧杆菌数量变化不明显,高、中和低剂量组肠杆菌数量均无明显变化;连续灌胃14 天,中、高剂量组双歧杆菌数量显著增加,高剂量组小鼠肠道乳杆菌数量显著增加,产气荚膜梭菌和肠球菌数量降低,其他剂量组无明显变化。低聚果糖还有润肠通便,缓解便秘的作用,低聚果糖是一种小分子量的水溶性膳食纤维,摄入后可刺激肠道蠕动,改变肠道内容物的渗透压,增加粪便水分,起到润肠通便、缓解便秘的作用。有人报道便秘患者每天服用低聚果糖5g,连续服用7天后,其排便次数增多,排便状况和排便性状得到改善,可见低聚果糖具有一定的通便作用。低聚果糖具有明显的促进肠道蠕动、增强通便的作用。有人通过建立小鼠便秘模型来探讨低聚果糖的通便功效,在不影响便秘模型小鼠生长发育的前提下,通过饲喂低聚果糖,小鼠小肠的推进作用增强,首便时间缩短,同时粪便粒数和粪便质量增加,证明了低聚果糖具有促进便秘模型小鼠排便的作用。低聚果糖作为一种膳食纤维,还具有结合金属离子的作用,在胃肠中可形成 FOS-矿物质络合物,该络合物到达大肠后,矿物质被释放出来。低聚果糖被肠道细菌发酵,产生乙酸、丙酸、丁酸等短链脂肪酸及乳酸等,降低肠道环境pH,抑制有害细菌和病源菌的生长繁殖,减少肠内毒素和腐败物质的产生和积累。肠道环境 pH 的降低,也有利于钙、镁等矿物质盐的溶解,从而促进机体对钙、镁等矿质元素的吸收。
果糖是一种甜味剂,也是人类的一种能量补充剂,与葡萄糖不同,果糖在人体内代谢比葡萄糖快,容易被机体吸收,且不依赖胰岛素,对血糖影响很小,适用于葡萄糖代谢及肝功能不全的患者补充能量,也是中老年人一种重要的能量补充剂,果糖同时还具有重要的促进肠道有益细菌繁殖的作用,可改善肠功能和代谢,对消化不良,习惯性便秘等有很好的改善重要,因此临床可以作为中老年人,特别是是糖尿病人、肥胖病人的理想甜味剂和保健食品的添加剂。
维生素C是一种水溶性维生素。食物中的维生素C被人体小肠上段吸收。维生素c进入肠道时,能促进畅内益生菌生长,维持良好的肠内环境及软化硬便作用;同时还有助于抑制食欲、加快脂肪燃烧速度例及促进人体的新陈代谢。自1899发现双歧杆菌以来,人类对其进行大量研究发现,双歧杆菌是人和某些动物肠道中对机体有益的菌类,尽管其对机体健康影响的一些机制还不甚明确,但该菌对机体具有生物屏障作用、对肝脏的保护和抗癌作用、营养及提高免疫机能作用和预防疾病传染的作用均已得到充分的肯定。双歧杆菌是严格厌氧菌,培养条件苛刻,生长十分缓慢,在肠道内或活菌制剂中存活率和生长速率较低。已经证明维生素C对双歧杆菌有较好的促进作用,我们研究发现,维生素C与菊粉、低聚果糖和果糖联合应用,对双歧杆菌的促进作用更加明显。维生素C在体内能抗自由基氧化,减少心肌耗氧量,增加冠脉血流量和心血输出量,促进心肌糖原转化,对心肌缺血和损伤有预防和修复作用,大剂量维生素C还具有抗心律失常作用,维生素C参与细胞间质形成,能促进胶原纤维和四氢叶酸形成,减少疼痛,降低毛细血管通透性和脆性,减少组织渗透,起到消肿和促进伤口愈合的作用。大剂量维生素C可增强白细胞的吞噬能力和诱导体内产生干扰素,干扰病毒 mRNA转录和 DNA复制,增强对感染的抵抗力,具有抗组胺以及抑制致癌物质生成的作用。维生素C临床常常应用坏血病、牙龈出血等病,还常常应用于感染及炎症,防治肿瘤,糖尿病。
发明内容
对中老年人的***衡、免疫功能、胃肠道发育及其它多种重要的生理活动。通过改变肠道微生物菌群,特别是促进益生菌的生长,对人体的健康是有利的,已有许多学者通过补充双歧杆菌等活的益生菌对便秘的患者进行了试验,也取得了一定的疗效,但人体是一个复杂的统一体,不同的人体体内的益生菌的组成是不同的,补充单一的或者混合的益生菌不是理想的办法,本项目希望找到一种更好的食品组合物,这些组合物能够很好地促进人体内益生菌生长,抑制非益生菌的生长,同时,还有调节肠道生理环境,促进肠道蛋白质等营养物质及矿物质的吸收,我们经过大量研究,发现菊粉、低聚果糖、维生素C与果糖合用,可以胶理想地达到上述目标。
本发明提出, 由菊粉、低聚果糖、维生素C与果糖四种成分,按照6~15:3~8:0.03~0.10:1~5份组成的组合物,应用温水冲稀溶解服用,就可以更好地调节肠道微生物菌群,促进肠道双歧杆菌等益生菌的数量,其中菊粉、低聚果糖可以促进肠道原有的益生菌的生长繁殖,维生素C也有促进肠道原有的益生菌成长,还可以调节益生菌的生长环境,抗病毒,促进免疫功能,果糖能够提供胃肠道的吸收和消化及肠蠕动的关键能量,更好促进胃肠道的吸收和消化功能,增强肠的蠕动功能,这四种物质的有效组合,就可以达到润肠通便,解除习惯性便秘,顽固性便秘等症状,同时,这种润肠通便的益生元,没有毒性,可以长期应用,特别适合中老年人保健及防治习惯性便秘。
具体实施方式
以下是本发明的具体实施例,对本发明的技术方案做进一步作描述,但是本发明的保护范围并不限于这些实施例,凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。
实施例一
益生元固体饮料:该固体饮料是由菊粉10份,低聚果糖4.45份,维生素C 0.05份,结晶果糖1.5份组成,经灭菌消毒,洁净包装为每小包8克,应用时每包用90-120毫升温水溶解后服用,每天两次,每次1包。
实施例二
益生元饮料:该饮料是由菊粉9份,低聚果糖4.45份,维生素C 0.05份,结晶果糖1.5份组成,加入清洁的纯化水,经无菌分装,灭菌,每瓶150毫升。
本研究配置的益生元饮料,通过动物实验观察了对小肠运动的作用及排便时间、粪便粒数和粪便质量测定,采用清洁级昆明种ICR小鼠100只,进行适应性喂养1 周后随机分成2 组,每组60只,分别进行小肠运动实验和排便实验。每组实验分别设低、中、高剂量组、空白对照组和模型对照组5组,每组10只。益生元饮料根据人体推荐量为15 g/d,设计为中剂量,高剂量是中剂量的2倍,低剂量为中剂量的0.5倍,空白对照组给予蒸馏水,模型对照组和3个剂量组灌胃给予小肠蠕动抑制剂复方地芬诺酯(5 mg/kg·bw)。实验为经口灌胃,容积为0.2 mL/10g,每天1次,连续灌胃15天。15天后各组小鼠禁食24小时。30分钟后,各剂量组给予含相应受试物的墨汁,空白和模型对照组给予墨汁灌胃。各组给墨汁25 min 后颈椎脱臼法处死动物,打开腹腔分离肠系膜,取出幽门至盲肠部的整段小肠,不加牵引平铺呈直线。测量小肠全长和幽门至墨汁运动前沿,按照小肠推进率/%=墨汁推进长度(cm)/小肠总长度计算小肠推进率。结果表明,模型对照组与空白对照组相比,小肠推进率明显减慢,有显著性差异(P<0.05),表明给予复方地芬诺酯后,小鼠小肠蠕动抑制模型建立成功。益生元饮料高中低三个剂量组小鼠小肠推进率明显增快,与模型对照组相比,差异具有显著性,中剂量与空白对照组相比,差异也有明显的显著性。为观察益生元饮料对小鼠排便时间、粪便粒数和粪便质量的影响,参照前面的实验方法进行给药,在给予复方地芬诺酯30min 后,各剂量组给予含相应受试物的墨汁,空白和模型对照给墨汁灌胃后,每组动物单独喂养,正常饮食进水。从给予墨汁开始,观察记录每只动物排出首粒黑便时间、6h内排黑便粒数及质量,同时观察粪便性状。结果表明,模型对照组小鼠的首次排便时间、粪便粒数、粪便重量与空白对照组相比具有显著差异,提示便秘小鼠模型建立成功。经口给予小鼠不同剂量受试物15d,与模型对照组相比,低、中、高剂量组益生元组小鼠的首次排便时间均有不同程度的缩短,粪便粒数、粪便重量均高于模型对照组,且存在一定程度的剂量效应关系,其中高剂量组具有显著性差异(P<0.05),表明益生元饮料可改善实验小鼠的排便功能,加速粪便排出。
益生元固体饮料,经200多例中老年习惯性便秘的患者临床使用,疗效特好,许多患者服用一到3天,就有明显的润肠通便的效果,服用一周以后,多数原来习惯性便秘的患者,原来较硬的粪便就会***,排便通畅。服用本品没有出现腹泻的症状,也没有出现其他不良反应。
Claims (3)
1.一种适合中老年便秘人群服用的益生元组合物,其特征在于该固体饮料是由菊粉6~15份,低聚果糖3~8份,维生素C 0.03~0.10份,结晶果糖1~5份组成。
2.如根据权利要求1所述的一种适合中老年便秘人群服用的益生元组合物,其特征在于其所述固体饮料是由菊粉10份,低聚果糖4.45份,维生素C 0.05份,结晶果糖1.5份组成;经灭菌消毒,洁净包装为每小包8克,应用时用每包用90-120毫升温水溶解后服用,每天两次,每次1包。
3.如根据权利要求1所述的一种适合中老年便秘人群服用的益生元饮料,其特征在于其所述的饮料的配方是由菊粉9份,低聚果糖4.45份,维生素C 0.05份,结晶果糖1.5份组成,加入清洁的纯化水,经无菌分装,灭菌,每瓶150毫升,即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810051008.9A CN108402371A (zh) | 2018-01-19 | 2018-01-19 | 一种适合中老年便秘人群服用的益生元组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810051008.9A CN108402371A (zh) | 2018-01-19 | 2018-01-19 | 一种适合中老年便秘人群服用的益生元组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108402371A true CN108402371A (zh) | 2018-08-17 |
Family
ID=63126076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810051008.9A Pending CN108402371A (zh) | 2018-01-19 | 2018-01-19 | 一种适合中老年便秘人群服用的益生元组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108402371A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109700031A (zh) * | 2018-12-19 | 2019-05-03 | 中恩(天津)医药科技有限公司 | 用于肠道清洁、肠道排毒的营养组合物 |
CN110638049A (zh) * | 2019-10-30 | 2020-01-03 | 山东若尧特医食品有限公司 | 一种改善肠道功能的碳水化合物固体制剂及其制备方法 |
CN112042748A (zh) * | 2020-09-09 | 2020-12-08 | 甘肃华羚生物技术研究中心有限公司 | 一种适用于中老年人群的牦牛乳益生菌粉及其制备工艺 |
CN112931883A (zh) * | 2021-03-24 | 2021-06-11 | 浙江屯屯麦生物技术开发有限公司 | 一种益生元组合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106472682A (zh) * | 2015-09-02 | 2017-03-08 | 钟虹光 | 一种乳制品 |
CN106509583A (zh) * | 2016-11-04 | 2017-03-22 | 浙江大学 | 一种含益生菌和益生元的食醋泡腾片及其制备方法 |
CN107412274A (zh) * | 2017-08-16 | 2017-12-01 | 山西亿科宏泰生物科技有限公司 | 一种治疗便秘的益生菌药物及其制备方法 |
CN107495383A (zh) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | 一种润肠通便复合益生元及其制备方法与应用 |
-
2018
- 2018-01-19 CN CN201810051008.9A patent/CN108402371A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106472682A (zh) * | 2015-09-02 | 2017-03-08 | 钟虹光 | 一种乳制品 |
CN106509583A (zh) * | 2016-11-04 | 2017-03-22 | 浙江大学 | 一种含益生菌和益生元的食醋泡腾片及其制备方法 |
CN107495383A (zh) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | 一种润肠通便复合益生元及其制备方法与应用 |
CN107412274A (zh) * | 2017-08-16 | 2017-12-01 | 山西亿科宏泰生物科技有限公司 | 一种治疗便秘的益生菌药物及其制备方法 |
Non-Patent Citations (5)
Title |
---|
刘协等: "低聚果糖的润肠通便功能研究 ", 《江苏预防医学》 * |
张春红等: "菊粉的特性及在特殊医学用途配方食品中的应用前景 ", 《中国酿造》 * |
彭珍等: "益生菌体外增殖因子的初步研究 ", 《中国微生态学杂志》 * |
王建 等: "双歧杆菌促生长因子的筛选", 《中国酿造》 * |
王翠苹等: "益生菌联合乳果糖对重症心脏瓣膜病术后腹腔内压的影响 ", 《中华普通外科学文献(电子版)》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109700031A (zh) * | 2018-12-19 | 2019-05-03 | 中恩(天津)医药科技有限公司 | 用于肠道清洁、肠道排毒的营养组合物 |
CN110638049A (zh) * | 2019-10-30 | 2020-01-03 | 山东若尧特医食品有限公司 | 一种改善肠道功能的碳水化合物固体制剂及其制备方法 |
CN112042748A (zh) * | 2020-09-09 | 2020-12-08 | 甘肃华羚生物技术研究中心有限公司 | 一种适用于中老年人群的牦牛乳益生菌粉及其制备工艺 |
CN112931883A (zh) * | 2021-03-24 | 2021-06-11 | 浙江屯屯麦生物技术开发有限公司 | 一种益生元组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7101565B2 (en) | Probiotic/prebiotic composition and delivery method | |
CN106619743A (zh) | 一种具有降血糖作用的益生菌固体饮料及其制备方法 | |
CN109430666A (zh) | 一种益生菌冻干粉固体饮料 | |
CN108402371A (zh) | 一种适合中老年便秘人群服用的益生元组合物 | |
CN109464487A (zh) | 抗幽门螺杆菌的益生菌复合物及其制备方法 | |
CN109419814B (zh) | 戈氏副拟杆菌用于抑制脂肪肝疾病的用途 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
CN110447799A (zh) | 一种用于改善肠道菌群的复合固体植物饮料及其制备方法 | |
CN105535580A (zh) | 一种用于改善人体肠道菌群的生物制剂及其制备方法 | |
CN110859871A (zh) | 一种用于***炎的组合物及其制备方法 | |
CN107095308A (zh) | 一种益生菌制剂及其应用 | |
CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
CN116549494B (zh) | 具有通便功能的β-1,3/α-1,3-葡聚糖复配组合物及其制备方法和用途 | |
CN105707378A (zh) | 黑青稞瘦身咖啡 | |
CN101849969A (zh) | 产酪酸有益菌在制备防治重症疾病肠道屏障损伤及损伤后并发症制剂中的应用 | |
KR20180122380A (ko) | 피칼리박테리움속 세균증식제 | |
CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
CN109700031A (zh) | 用于肠道清洁、肠道排毒的营养组合物 | |
CN102283971A (zh) | 一种治疗各类胃炎的中成药 | |
CN108904484A (zh) | 一种没食子酸乙酯的用途 | |
Johnson | New food components and gastrointestinal health | |
CN108245531A (zh) | 一种改善胃肠道功能、防治便秘的组合物 | |
CN115297878A (zh) | 用于增强人受试者中尿石素产生的组合物 | |
CN101199492A (zh) | 低聚木糖、木糖醇在包衣片包衣中的应用 | |
CN100553649C (zh) | 一种调节肠道菌群和提高缺氧耐受力的组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180817 |